Patents Examined by Jennifer Graser
  • Recombinantly expressed CelTOS antigen and methods of use thereof
    Patent number: 9120868
    Abstract: A synthetic nucleotide, which transcribes as the cell-traversal protein for ookinetes and sporozoites (CelTOS) antigen of Malaria Plasmodium, and methods of use thereof.
    Type: Grant
    Filed: November 23, 2009
    Date of Patent: September 1, 2015
    Assignee: The United States of America as Represented by the Secratary of the Army
    Inventors: Evelina Angov, Elke Bergmann-Leitner, Christian Ockenhouse
  • Methods, devices, kits and compositions for detecting roundworm
    Patent number: 9103823
    Abstract: Methods, devices, kits and compositions for detecting the presence or absence of roundworm in a fecal sample are disclosed herein. The methods, devices, kits and compositions of the present invention may be used to confirm the presence or absence of roundworm in a fecal sample from a mammal that may also be infected with one or more of hookworm, whipworm, and heartworm. Confirmation of the presence or absence of roundworm in the mammal may be made, for example, for the purpose of selecting an optimal course of treating the mammal and/or for the purpose of determining whether the mammal has been rid of the infection after treatment has been initiated.
    Type: Grant
    Filed: October 3, 2013
    Date of Patent: August 11, 2015
    Assignees: Idexx Laboratories, Inc., Divergence, Inc.
    Inventors: David Allen Elsemore, Laurie A. Flynn, Jinming Geng, Michael Crawford
  • Serologic correlates of protection against infection
    Patent number: 9102742
    Abstract: Regions of B. anthracis protective antigen are provided representing sequences recognized by antibodies in subjects that have vaccine induced lethal toxin neutralizing anti-PA IgG responses. The recognition of these PA regions enhances the utility of anti-PA IgG reactivity as an immune correlate of protection against anthrax in a subject and increases predictive probability of survival. Also provided are vaccines that include at least one of these PA regions that when administered to a subject improve the predictive value of vaccine induced anti-PA IgG and TNA responses as immune correlates of protection against inhalation anthrax.
    Type: Grant
    Filed: August 27, 2013
    Date of Patent: August 11, 2015
    Assignee: The United States of America as represented by the Secretary, Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Vera A. Semenova, Conrad P. Quinn, Jan Pohl, Pavel Svoboda, Shannon Dalton, Jarad M. Schiffer
  • Selection of RNA-aptamers as anti-malaria agents
    Patent number: 9096857
    Abstract: The present invention relates to an aptamer or an active fragment thereof raised against the semi-conserved duffy binding ligand domain 1?, DBL1?, region of the Plasmodium falciparum erythrocyte membrane protein 1, PfEMPI, which aptamer has an effect against malaria, in particular severe cerebral malaria.
    Type: Grant
    Filed: February 5, 2009
    Date of Patent: August 4, 2015
    Assignee: APTAHEM AB
    Inventors: Johan Lindh, Tina Persson
  • Methods and compositions involving protective staphylococcal antigens
    Patent number: 9095540
    Abstract: The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a Staphylococcus bacterium. The invention provides methods and compositions for stimulating an immune response against the bacteria. In certain embodiments, the methods and compositions involve a non-toxigenic Protein A (SpA) variant. In some embodiments, the methods and compositions involve SdrD, ClfA, and/or FnbpB polypeptides.
    Type: Grant
    Filed: September 9, 2011
    Date of Patent: August 4, 2015
    Assignee: The University of Chicago
    Inventors: Olaf Schneewind, Alice G. Cheng, Dominique M. Missiakas, Hwan Keun Kim, Hye-Young Kim
  • Gram-positive bacteria specific binding compounds
    Patent number: 9090677
    Abstract: The present invention provides improved binding compounds capable of specifically binding Gram-positive bacteria. Binding compounds are provided that are fully human, enabling therapeutic applications in human individuals.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: July 28, 2015
    Assignee: Genentech, Inc.
    Inventors: Tim Beaumont, Mark Jeroen Kwakkenbos, Eric J. Brown, John Hiroshi Morisaki, Wouter L. W. Hazenbos, Sanjeev Mariathasan, Kimberly Kajihara, Yi Xia
  • Recombinant mycobacterium as vaccine for use in humans
    Patent number: 9084749
    Abstract: The invention relates to a recombinant vaccine providing protective immunity especially against tuberculosis in human subjects.
    Type: Grant
    Filed: September 16, 2011
    Date of Patent: July 21, 2015
    Assignee: Vakzine Projekt Management GmbH
    Inventor: Leander Grode
  • Combinations comprising a fungicidal strain and an active compound
    Patent number: 9078447
    Abstract: Fungicidal mixtures, comprising 1) a fungicidal strain (I) selected from a) the Bacillus substilis strain with NRRL Accession No. B-21661, and b) the Bacillus pumilus strain with NRRL Accession No. B-30087, or a mutant of these strains having all the identifying characteristics of the respective strain, or a metabolite produced by the respective strain that exhibits activity against plant pathogenic fungi, and 2) at least one chemical compound II, selected from the active compound groups A) to F): A) azoles; B) strobilurins; C) carboxamides; D) heterocyclic compounds; E) carbamates; F) other fungicides; in a synergistically effective amount, methods for controlling harmful fungi using compositions of components 1) and 2), the use of a component 1) with a component 2) for preparing such compositions, and also fungicidal agents and seed comprising such compositions.
    Type: Grant
    Filed: September 16, 2008
    Date of Patent: July 14, 2015
    Assignee: Bayer CropScience LP
    Inventors: Ulrich Schoefl, Maria Scherer, Egon Haden
  • LprG as a chaperone of immune adjuvants
    Patent number: 9078875
    Abstract: An adjuvant combination that stimulates immune activation or response includes a hydrophobic immune adjuvant and a pathogen derived lipoprotein that chaperones the hydrophobic immune adjuvant to an immune receptor.
    Type: Grant
    Filed: February 28, 2013
    Date of Patent: July 14, 2015
    Assignee: Case Western Reserve University
    Inventors: Clifford Harding, W. Henry Boom, Michael G. Drage, Nicole D. Pecora
  • Compositions and methods for treatment of microbial infections
    Patent number: 9072694
    Abstract: The present invention relates to methods and compositions for treatment of microbial infections and for the enhancement of resistance to infection. The invention comprises administration of an effective amount of a protein isolated from bacterial lysate compositions for the treatment of pathological conditions of microbial infections. The present invention can also be used to enhance the immune system to prevent infections by the administration of an effective amount of the compositions.
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: July 7, 2015
    Assignee: IMMUNOLOGY LABORATORIES, INC.
    Inventors: Jiri Pillich, John C. Balcarek
  • Vaccines
    Patent number: 9066899
    Abstract: The invention relates to use of an antigen derived from the circumsporozoite protein (CS) protein of Plasmodium falciparum which is expressed at the pre-erythrocytic stage of malarial infection in combination with a pharmaceutically acceptable adjuvant, in the manufacture of a medicament for vaccinating infants against malaria.
    Type: Grant
    Filed: August 11, 2008
    Date of Patent: June 30, 2015
    Assignee: GLAXOSMITHKLINE BIOLOGICALS SA
    Inventors: William Ripley Ballou, Joseph D Cohen
  • Viable gram negative bacteria lacking outer membrane agonists of TLR4/MD-2
    Patent number: 9068186
    Abstract: Viable Gram-negative bacteria or components thereof comprising outer membranes that substantially lack a ligand, such as Lipid A or 6-acyl lipidpolysaccharide, that acts as an agonist of TLR4/MD2. The bacteria may comprise reduced activity of arabinose-5-phosphate isomerases and one or more suppressor mutations, for example in a transporter thereby increasing the transporters capacity to transport Lipid IVA or in membrane protein YhjD. One or more genes (e.g., IpxL, IpxM, pagP, IpxP, and/or eptA) may be substantially deleted and/or one or more enzymes (e.g., LpxL, LpxM, PagP, LpxP, and/or EptA) may be substantially inactive. The bacteria may be competent to take up extracellular DNA, may be donor bacteria, or may be members of a library. The present invention also features methods of creating and utilizing such bacteria.
    Type: Grant
    Filed: March 11, 2011
    Date of Patent: June 30, 2015
    Assignee: RESEARCH CORPORATION TECHNOLOGIES, INC.
    Inventors: David Bramhill, Uwe Mamat
  • Use of flagellins from the genus as vaccination adjuvants
    Patent number: 9061002
    Abstract: Use of flagellins from the genus Marinobacter as vaccine adjuvants. This invention is based on the use of two recombinant flagellins, F and FR, from the species Marinobacter algicola (DG893T strain), as vaccine adjuvants capable of developing a specific immune response, against peptides or proteins fused to said flagellins, or administered unfused jointly with the flagellins. This invention also describes new combined vaccination strategies, based on the two Marinobacter algicola flagellins and the Salmonella typhimurium flagellin.
    Type: Grant
    Filed: February 2, 2010
    Date of Patent: June 23, 2015
    Assignee: INSTITUTO NACIONAL DE INVESTIGACIÓN TECNOLOGÍA AGRARIA Y ALIMENTARIA (INIA)
    Inventor: Eduardo Gómez Casado
  • Vaccine and methods of use against infection
    Patent number: 9056068
    Abstract: The polynucleotide encoding the SSIR gene from the nematode Strongyloides stercoralis is provided, along with the polypeptide encoded by the SSIR gene. It was found that when mice were immunized with the SSIR polypeptide vaccine, it provided immunity to mice which were implanted with Strongyloides stercoralis L3 implants. Methods for making the SSIR protein, recombinant vectors encoding the SSIR gene, a vaccine made from the SSIR protein, and methods of use are also provided.
    Type: Grant
    Filed: February 1, 2011
    Date of Patent: June 16, 2015
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Thomas Jefferson University
    Inventors: Thomas B. Nutman, David Abraham
  • avirulent adjuvanted live vaccine
    Patent number: 9056909
    Abstract: Provided are immunogenic and vaccine compositions and methods for their preparation and use, which compositions are effective in protecting against, minimizing the severity of, preventing, and/or ameliorating M. hyopneumoniae infection. Administration to an animal of one or two doses of an adjuvanted live avirulent M. hyopneumoniae composition disclosed herein is effective in providing immunity to the animal and protection from infection with a virulent strain of M. hyopneumoniae thereby reducing the severity of and/or preventing disease caused by one or more virulent strain of M. hyopneumoniae. Also provided are compositions, which further comprise one or more antigen such as, for example, one or more live bacteria, bacterin, toxoid, and/or virus and/or viral antigen. Exemplified are immunogenic compositions, comprising an adjuvanted live avirulent M.
    Type: Grant
    Filed: November 5, 2008
    Date of Patent: June 16, 2015
    Assignee: Zoetis Services LLC
    Inventors: Hsien-Jue Chu, Zhichang Xu, Wumin Li, Nicole Rae Gibson
  • Serologic correlates of protection against infection
    Patent number: 9046520
    Abstract: Regions of Bacillus anthracis protective antigen are provided representing epitopes recognized by antibodies in subjects that have acquired immunity to Bacillus anthracis infection. The recognition of these epitopes correlates with autoimmunity in a subject. Also provided are vaccines that include at least one of these epitopes that when administered to a subject provide improved acquired immunity.
    Type: Grant
    Filed: February 10, 2011
    Date of Patent: June 2, 2015
    Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Vera A. Semenova, Conrad P. Quinn, Jan Pohl, Pavel Svoboda
  • Genes of an otitis media isolate of nontypeable
    Patent number: 9034642
    Abstract: The invention relates to the polynucleotide sequence of a nontypeable strain of Haemophilus influenzae (NTHi) and polypeptides encoded by the polynucleotides and uses thereof. The invention also relates to NTHi genes which are upregulated during or in response to NTHi infection of the middle ear and/or the nasopharynx.
    Type: Grant
    Filed: January 9, 2014
    Date of Patent: May 19, 2015
    Assignees: NATIONWIDE CHILDREN'S HOSPITAL, THE BOARD OF REGENTS OF UNIVERSITY OF OKLAHOMA
    Inventors: Lauren O. Bakaletz, Robert S. Munson, Jr., David W. Dyer
  • Synergistic bacterial compositions and methods of production and use thereof
    Patent number: 9028841
    Abstract: Provided are therapeutic compositions containing Ecobiotic™ populations for prevention, treatment and reduction of symptoms associated with a dysbiosis of a mammalian subject such as a human.
    Type: Grant
    Filed: March 20, 2014
    Date of Patent: May 12, 2015
    Assignee: Seres Health, Inc.
    Inventors: Matthew R. Henn, Geoffrey von Maltzahn, Anthony Mario D'Onofrio, Kevin Daniel Litcofsky, David A. Berry, David N. Cook, Noubar B. Afeyan, John Grant Aunins
  • Production of a viable, storable worm egg suspension
    Patent number: 9017700
    Abstract: The present application describes a novel, advantageous purification method which guarantees the embryonation capability and the viability of a worm egg suspension. The T. suis worm eggs are first treated in a non-embryonated condition in a sulfuric acid solution at about =ph 2. Bacteria and viruses are thereby killed successfully. The germination number of yeasts and fungi is reduced. In a second step, the pH-value is increased and an orally tolerated preservative is added. Yeasts and fungi are thereby killed successfully. The suspension medium used in the second purification step can then be used as a culture medium for additional production (embryonation) and storage.
    Type: Grant
    Filed: March 31, 2008
    Date of Patent: April 28, 2015
    Assignee: Dr. Falk Pharma GmbH
    Inventors: Rudolf Wilhelm, Allan Kund Roepstorff, Christian Moliin Outzen Kapel
  • Compositions and methods for modulating immune responses
    Patent number: 9017697
    Abstract: This invention discloses methods and compositions for modulating immune responses, which involve particulate delivery of agents to immune cells, wherein the agents comprise an inhibitor of the NF-?B signaling pathway and an antigen that corresponds to a target antigen. The methods and compositions of the present invention are particularly useful in the treatment or prophylaxis of an undesirable immune response associated with the target antigen, including autoimmune diseases, allergies and transplantation associated diseases.
    Type: Grant
    Filed: October 12, 2007
    Date of Patent: April 28, 2015
    Assignee: The University of Queensland
    Inventors: Ranjeny Thomas, Nigel Meredith Davies, Brendan John O'Sullivan